Key Takeaways
- Shares of AbCellera surged 32% to $9.12 following positive Phase 2 trial results for menopause drug ABCL635
- ABCL635 delivered a single 600mg dose that decreased hot flash frequency by 8.8 episodes daily compared to 3.5 for placebo
- Trial participants experienced reduced symptom intensity and enhanced sleep quality
- The study included 92 postmenopausal women in a randomized, double-blind, placebo-controlled design
- The four-week treatment period concluded without any serious adverse events
Shares of AbCellera (ABCL) rallied 32% to reach $9.12 during Monday’s trading session following the release of encouraging Phase 2 clinical trial data for its menopause treatment candidate.
AbCellera Biologics Inc., ABCL
Prior to Monday’s session, the stock had already seen its value more than double throughout 2026, with much of that momentum fueled by investor expectations surrounding this clinical data announcement.
The experimental therapy ABCL635 represents a non-hormonal, extended-duration treatment administered via a single injection beneath the skin. The drug works by targeting the neurokinin 3 receptor, a biological mechanism involved in initiating hot flash episodes.
The Phase 2 clinical study recruited 92 women in postmenopause who were suffering from approximately 10 moderate-to-severe hot flash episodes daily. Study participants were randomly assigned to receive either a single 600mg subcutaneous injection of ABCL635 or an inactive placebo.
At the four-week mark, the trial successfully achieved its primary efficacy goals. This indicates the treatment met the predetermined statistical benchmarks required for the company to declare the study successful.
Trial Results Breakdown
Regarding hot flash frequency, participants receiving ABCL635 experienced a reduction of 8.8 moderate-to-severe episodes per day from their starting baseline. Those in the placebo group saw a decrease of 3.5 episodes. This translates to a placebo-adjusted benefit of 5.3 fewer episodes daily.
For severity measurements, the drug decreased scores by 1.4 points at the four-week assessment versus 0.3 points for placebo recipients, representing a placebo-adjusted improvement of 1.1 points.
Women who received ABCL635 also documented improved sleep patterns and an overall enhancement in their well-being, according to patient global impression of change assessments.
The study followed a randomized, double-blind, placebo-controlled framework, which represents the gold standard methodology for this category of clinical research.
Safety and Tolerability
ABCL635 demonstrated good tolerability throughout the four-week study duration. Researchers reported zero serious adverse events, zero severe adverse events, and no study discontinuations attributed to treatment-related side effects.
Among participants receiving ABCL635, the most frequently observed side effects included headache, fatigue, and reactions at the injection site.
AbCellera conducted a conference call on Monday to review the trial outcomes with the investment community and research analysts.
The biotechnology company is marketing ABCL635 as a non-hormonal alternative, which could prove significant for patients unable to use or who prefer to avoid hormone replacement therapies.
ABCL stock finished Monday’s trading session at $9.12, representing a 32% gain for the day.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
